杭州华浙生物医药有限公司

杭州华浙生物医药有限公司

浙江省杭州市浙江省杭州市余杭区仓前街道欧美金融城2幢 2009 室1号

2022.12

20至29

20,000,000至24,999,999

杭州华浙生物医药有限公司 成立于2022年12月，公司前身为南京华兴医药科技有限公司中间体事业部，2022年独立后自主经营发展并获得进出口权。 现主营业务覆盖医药、兽药中间体，原料药，保健品等产品研发、生产及国内外销售等，2024年销售额突破1亿元人民币。公司技术储备充足，已商业化销售成熟中间体208个，每年开发中间体-API项目10-20个。 公司在南京、台州设有研发和中试实验室；在福建明溪、黑龙江鸡西、哈尔滨兰西、湖北荆州等地都有合作生产基地。工厂已通过美国FDA、欧盟EDQM、中国NMPA等cGMP现场检查。 Hangzhou Huazhe Biopharmaceuticals Co., Ltd. was established in December 2022. It was formerly the Pharmaceutical intermediate department of Nanjing Huaxing Pharmaceutical Technology Co., Ltd. and became independent in 2022 with the right to import and export. The current main business covers the R&D, production and domestic and foreign sales of products such as pharmaceutical and veterinary intermediates, APIs and healthcare products.In 2024, the company's sales exceeded 100 million RMB. With abundant technical reserves, it has commercialized 208 mature intermediates and develops 10- 20 intermediate- API projects annually.    

经验丰富的研发人员,发货速度,生产能力,良好的信誉,优质服务

735200

制造商,分销商,出口商,贸易公司

中国,中/南美洲,中东,非洲,亚洲

Ixazomib citrate（1239908-20-3）;Elacestrant dihydrochloride(1349723-93-8);Ruxolitinib phosphate (1092939-17-7);Belumosudil Mesylate(2109704-99-4);Daprodustat(960539-70-2);Diquafosol tetrasodium(211427-08-6);Valsartan Sacubitril(936623-90-4);Finerenone(1050477-31-0);Zuranolone(1632051-40-1);Relugolix(737789-87-6);Levetiracetam(102767-28-2);Azacitidine(320-67-2);Cytarabine( 147-94-4);Mirogabalin besylate(1138245-21-2);Vonoprazan fumarate(1260141-27-2);Galantamine Hydrobromide(1953-04-4);Lincomycin(154-21-2);Tilmicosin Phosphate(137330-13-3);Tulathromycin(217500-96-4);Doxycycline(564-25-0);Florfenicol(73231-34-2);Thiamphenicol(15318-45-3);Clindamycin hydrochloride(21462-39-5);Carbasalate calcium(5749-67-7);Elacestrant-SM1(722536-73-4);Elacestrant-SM2(123027-99-6);Elacestrant-SM3(2477812-42-1);Elacestrant-B(2477812-37-4);Elacestrant-D(722520-36-7);Elacestrant-F(2477812-39-6);Elacestrant-H(2477812-41-0);2-(2,5-dichlorobenzamido)acetic acid(667403-46-5);2,5-Dichloro-N-[2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxoethyl]benzamide(1201903-02-7);1,3-Dicyclohexylbarbituric acid(35824-91-0);N-[(1,3-Dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]glycine ethyl ester(960540-96-9);Relugolix-B(308831-94-9);Relugolix-D(1589503-97-8);Relugolix-E(1589503-95-6);Elagollix-E(830346-47-9);Elagollix-F1(830346-48-0);Elagollix-F(1150560-54-5);Elagollix-(1150560-59-0);Methyl 2-(4-methylphenylsulfonamido)acetate(2645-02-5);methyl 4-hydroxy-7-phenoxyisoquinoline-3-carboxylate(1455091-10-7);Methyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate(1421312-34-6);1-(3,5-Dichlorophenyl)-2,2,2-trifluoroethanone(130336-16-2);4-acetyl-2-methylbenzoic acid(55860-35-0);2-amino-N-(2,2,2-trifluoroethyl)acetamide hydrochloride(1171331-39-7);4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid(864725-62-2);4-acetyl-1-naphthoic acid(131986-05-5);1-[3-Chloro-5-trifluoromethylphenyl]-2,2,2-trifluoroethanone(1125812-58-9)

第二十三届世界制药原料中国展

2025-03-06至2025-07-31

E12D58

Active Pharmaceutical Ingredients;Intermediates & Fine Chemicals;Veterinary Drug & Feed Additives